InspireMD (NSPR)
(Real Time Quote from BATS)
$2.38 USD
-0.05 (-2.06%)
Updated Jul 18, 2024 03:28 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NSPR 2.38 -0.05(-2.06%)
Will NSPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NSPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NSPR
Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
NSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Other News for NSPR
InspireMD management to meet with Piper Sandler
InspireMD management to meet with Piper Sandler
InspireMD Unveils Updated Investor Presentation Online
InspireMD’s CGuard Stent Shows Promise in C-GUARDIANS Trial
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024